Hemolysis Safety Evaluation of Medical Devices: Standards, Methods, and Regulatory Requirements

Hemolysis safety evaluation is a fundamental hemocompatibility test required for medical devices that contact blood, measuring the degree of red blood cell damage caused by device materials or extracts. This article provides a comprehensive technical guide covering ISO 10993-4 and ASTM F756 standards, sample requirements, direct and indirect testing methods, hemolysis rate calculation, and acceptance criteria for global regulatory submissions.

Technical Overview

Hemolysis safety evaluation is a critical component of the biological evaluation of medical devices that come into direct or indirect contact with circulating blood. Hemolysis refers to the rupture of red blood cells (erythrocytes) and the subsequent release of hemoglobin into the surrounding plasma or test medium. When device materials, surface coatings, residual manufacturing chemicals, or leachables damage erythrocyte membranes, the resulting free hemoglobin can cause anemia, renal injury, and systemic toxicity in patients.

The evaluation is primarily governed by ISO 10993-4 (Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood), which identifies hemolysis as one of the five key categories of hemocompatibility assessment alongside thrombosis, coagulation, platelet function, and complement activation. In the United States, ASTM F756 (Standard Practice for Analysis of Hemolytic Properties of Materials) provides detailed procedural guidance. In China, GB/T 16886.4 is the national standard harmonized with ISO 10993-4, and it is a mandatory consideration for NMPA device registration of blood-contacting products.

The quantitative endpoint of the test is the hemolysis rate (hemolysis index), calculated from spectrophotometric measurements of free hemoglobin. A device or material is generally considered non-hemolytic when the calculated hemolysis rate is below 5% relative to positive and negative controls. For blood-contacting devices intended for extracorporeal circulation, cardiovascular implants, and transfusion or infusion equipment, this test is routinely expected by regulatory authorities worldwide, including under the FDA 510(k) and PMA pathways, the EU MDR, and NMPA technical review.

Testing Samples

Blood-Contacting External Communicating Devices

Devices that communicate with the blood stream externally, such as intravenous catheters, cannulae, infusion sets, hemodialyzers, extracorporeal membrane oxygenation (ECMO) circuits, blood oxygenators, cardiopulmonary bypass tubing, and blood collection or apheresis systems, represent the largest category of samples requiring hemolysis evaluation. Both the device body materials and any fluid pathways that convey blood should be assessed.

Cardiovascular Implant Devices

Long-term or permanent implants in contact with circulating blood, including coronary and peripheral vascular stents, heart valves, vascular grafts, stent grafts, artificial hearts, ventricular assist devices, and embolic protection devices, require hemolysis testing as part of their hemocompatibility portfolio. Surface finish, coating integrity, and shear-induced mechanical effects are key considerations for these samples.

Raw Materials and Surface Coatings

Polymeric resins, elastomers, metal alloys, hydrophilic coatings, antithrombotic coatings, and drug-eluting surfaces submitted for material screening are tested in standardized geometries (for example, strips or discs of defined surface area) to determine intrinsic hemolytic potential before device-level design freezing.

Blood Contacting Containers and Accessories

Blood bags, transfusion sets, syringes, stopcocks, filters, and blood warming systems that contact donated blood or blood products prior to reinfusion also fall within the scope of hemolysis safety evaluation.

Testing Items

The hemolysis safety evaluation program typically includes the following measurable items and parameters:

• Hemolysis rate (hemolysis index) by the direct contact method, expressed as a percentage relative to controls.
• Hemolysis rate by the indirect contact (extraction) method using physiological saline or other media under defined extraction conditions.
• Absorbance of free hemoglobin in the supernatant measured by ultraviolet-visible spectrophotometry at approximately 545 nm, the characteristic absorption wavelength of hemoglobin.
• Plasma-free hemoglobin concentration for dynamic or in vitro circulation test setups involving whole devices.
• Negative control response verification (typically high-density polyethylene or 0.9% sodium chloride injection).
• Positive control response verification (typically a known hemolyzing agent such as saponin, Triton X-100, or sterile water for injection).
• Supplementary hematological endpoints where required, including erythrocyte counts, hematocrit changes, and morphological observation of erythrocytes.

Testing Methods

Direct Contact Method

In the direct contact method, the sterile test sample is placed in direct contact with diluted fresh anticoagulated blood, typically rabbit blood or healthy human blood of a specified type, anticoagulated with heparin or sodium citrate. A common dilution is 8 mL of blood added to 10 mL of 0.9% sodium chloride injection. The sample-blood mixtures, together with negative and positive control groups, are incubated at 37°C for a defined period, commonly 2 to 4 hours, with three replicate tubes per group. After incubation, the tubes are centrifuged, and the absorbance of each supernatant is measured spectrophotometrically at 545 nm. The direct method best reflects the hemolytic potential of solid materials with significant surface contact.

Indirect Contact (Extraction) Method

In the indirect method, an extract of the test material is first prepared by incubating the sample in 0.9% sodium chloride injection or another appropriate vehicle at 37°C for a defined extraction period, frequently 24 hours, following the extraction ratio principles of ISO 10993-12. The resulting extract is then mixed with diluted blood and incubated at 37°C. This approach evaluates hemolytic substances that migrate from the material and is preferred for devices where leachables rather than surface contact are the primary concern, and for irregularly shaped or absorbent devices.

Dynamic Circulation Method

For complete extracorporeal circuits, oxygenators, and blood pumps, a dynamic method may be applied in which blood is circulated through the assembled device under controlled flow and shear conditions for several hours. This method captures mechanically induced hemolysis caused by flow turbulence, high shear stress at narrow lumens, and roller pump occlusion, in addition to material-induced hemolysis.

Calculation of Hemolysis Rate

The hemolysis rate is calculated using the mean absorbance values of the test, negative control, and positive control groups according to the following widely accepted formula:

Hemolysis rate (%) = [(Mean OD of test sample − Mean OD of negative control) ÷ (Mean OD of positive control − Mean OD of negative control)] × 100%

A result below 5% is generally interpreted as indicating that the device or material is non-hemolytic and acceptable for its intended blood-contacting application. Results between 5% and 10% typically warrant investigation and risk justification, while results above 10% are considered clearly hemolytic and unacceptable. Test validity requires that the positive control produces marked hemolysis and the negative control remains essentially non-hemolytic, confirming system sensitivity.

Quality and Laboratory Considerations

Testing should be performed by accredited third-party laboratories or in-house facilities operating under ISO/IEC 17025 quality systems. Blood must be freshly collected and used within a validated time window, typically within a few hours of collection, and anticoagulant type must not interfere with hemoglobin measurement. Glassware and consumables must be endotoxin-controlled where applicable, and hemoglobin contamination or incomplete centrifugation must be excluded as sources of error. Optical interference from colored extracts should be addressed by including sample blanks.

Applications

Hemolysis safety evaluation serves multiple purposes across the medical device product lifecycle:

• Regulatory registration submissions, including FDA 510(k) premarket notifications and PMA applications, EU MDR CE technical documentation, and NMPA registration dossiers for China market access, where ISO 10993-4 hemocompatibility data are routinely requested for blood-contacting devices.
• Design input and material selection during research and development, allowing early screening of polymers, metal alloys, plasticizers, and surface treatments for hemolytic potential.
• Verification of manufacturing and sterilization changes, such as a new sterilization modality, altered molding parameters, a new supplier of raw resin, or revised cleaning processes, which may introduce hemolytic residues.
• Support of biological safety evaluations and risk management files under ISO 10993-1 and ISO 14971, documenting that blood damage risk is controlled to acceptable levels.
• Benchmarking and competitive analysis of hemocompatibility performance for marketed products such as hemodialysis membranes, ECMO oxygenators, and vascular access devices.

FAQ

Which devices require hemolysis testing?

Under ISO 10993-4, devices are classified by blood contact category and duration. External communicating devices (catheters, cannulae, extracorporeal circuits) and blood-contacting implants (stents, grafts, valves) are expected to undergo hemolysis evaluation. Devices with indirect blood contact, such as infusion sets that deliver fluids intravenously, are also commonly evaluated. A device may justify omission through a documented rationale, but for most blood-contacting products, hemolysis data are expected by reviewers.

What is the acceptance criterion for hemolysis rate?

The widely accepted criterion is a hemolysis rate below 5%, calculated against positive and negative controls. This threshold originates from historical pharmacopeial and national standard practice and is applied by ASTM F756 and referenced in numerous regulatory guidance documents. A rate of 5% or greater generally triggers redesign, material substitution, or a detailed scientific justification.

Should the direct or indirect method be used?

The choice depends on the device geometry and the anticipated mechanism of blood damage. The direct contact method suits solid materials and finished surfaces where physical contact dominates. The extraction method suits devices where leachable substances are the concern or where sample geometry prevents controlled direct contact. Many evaluation programs include both methods to cover surface-related and leachate-related hemolysis. Dynamic circulation testing is added for pump-driven extracorporeal systems.

What blood source is used for testing?

Fresh rabbit blood collected with heparin anticoagulation is the traditional and most common source specified in many national standards, including GB/T 16886-based practice. Fresh healthy human blood, anticoagulated with heparin or acid-citrate-dextrose, may also be used and can provide clinically relevant results. Whichever source is selected, collection, dilution, and time-to-use must be validated, and ethical requirements for human blood use must be met.

How is hemolysis testing related to other hemocompatibility tests?

Hemolysis addresses only the hematological cell damage category of ISO 10993-4. A complete hemocompatibility assessment for high-risk devices may also include thrombosis testing, coagulation assays such as PT, APTT, and thrombin generation, platelet activation and aggregation studies, complement activation (C3a, C5a, SC5b-9), and leukocyte counts. The specific panel is tailored to the device's blood contact category, contact duration, and intended use.

How long does a hemolysis test take?

The core laboratory phase is short, typically one to two days including blood collection, incubation, centrifugation, and spectrophotometric analysis. However, the complete process including sample sterilization to match the clinical state, extraction conditioning where required, and report issuance generally takes one to two weeks. Scheduling is often governed by blood availability at the testing facility.